Literature DB >> 12941151

Arginase and autoimmune inflammation in the central nervous system.

Lingyun Xu1, Brendan Hilliard, Ruaidhrí J Carmody, Galit Tsabary, Hyunshun Shin, David W Christianson, Youhai H Chen.   

Abstract

Using a high throughput gene microarray technology that detects approximately 22 000 genes, we found that arginase I was the most significantly up-regulated gene in the murine spinal cord during experimental autoimmune encephalomyelitis (EAE). By Northern blot and arginase enzyme assay, we detected high levels of arginase I mRNA and protein, respectively, in the spinal cord of EAE mice, but not in the spinal cord of normal mice or mice that had recovered from EAE. In vitro, both microglia and astrocytes produced arginase and nitric oxide synthase, two enzymes that are involved in arginine metabolism. To explore the roles of arginase in EAE, we injected the arginase inhibitor amino-6-boronohexanoic acid (ABH) into mice during the inductive and effector phases of the disease. Compared with mice that received vehicle control, mice treated with ABH developed milder EAE with delayed onset, reduced disease score and expedited recovery. Spleen mononuclear cells from ABH-treated mice produced more nitric oxide and secreted less interferon-gamma and tumour necrosis factor-alpha as compared to control mice. These results indicate that arginase plays important roles in autoimmune inflammation in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941151      PMCID: PMC1783013          DOI: 10.1046/j.1365-2567.2003.01713.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  SIN-1, a nitric oxide donor, ameliorates experimental allergic encephalomyelitis in Lewis rats in the incipient phase: the importance of the time window.

Authors:  L Y Xu; J S Yang; H Link; B G Xiao
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

2.  Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism.

Authors:  M Hesse; M Modolell; A C La Flamme; M Schito; J M Fuentes; A W Cheever; E J Pearce; T A Wynn
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

3.  Nitric oxide plays a critical role in the recovery of Lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction.

Authors:  N C O'Brien; B Charlton; W B Cowden; D O Willenborg
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

4.  Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells.

Authors:  M Munder; K Eichmann; J M Morán; F Centeno; G Soler; M Modolell
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

5.  Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites.

Authors:  Virginia Iniesta; L Carlos Gómez-Nieto; Isabel Molano; Alicia Mohedano; Jesualdo Carcelén; Cristina Mirón; Carlos Alonso; Inés Corraliza
Journal:  Parasite Immunol       Date:  2002-03       Impact factor: 2.280

6.  Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis.

Authors:  B Hilliard; A Wilmen; C Seidel; T S Liu; R Göke; Y Chen
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

7.  M-1/M-2 macrophages and the Th1/Th2 paradigm.

Authors:  C D Mills; K Kincaid; J M Alt; M J Heilman; A M Hill
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

8.  Differential roles of Fas ligand in spontaneous and actively induced autoimmune encephalomyelitis.

Authors:  T S Liu; B Hilliard; E B Samoilova; Y Chen
Journal:  Clin Immunol       Date:  2000-06       Impact factor: 3.969

9.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.

Authors:  K Song; Y Chen; R Göke; A Wilmen; C Seidel; A Göke; B Hilliard; Y Chen
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

10.  The inhibition of arginase by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages.

Authors:  V Iniesta; L C Gómez-Nieto; I Corraliza
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

View more
  43 in total

1.  Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?

Authors:  Amir A Zeki; Jennifer M Bratt; Michelle Rabowsky; Jerold A Last; Nicholas J Kenyon
Journal:  Transl Res       Date:  2010-12       Impact factor: 7.012

2.  Crystal structure of human arginase I complexed with thiosemicarbazide reveals an unusual thiocarbonyl mu-sulfide ligand in the binuclear manganese cluster.

Authors:  Luigi Di Costanzo; Michael E Pique; David W Christianson
Journal:  J Am Chem Soc       Date:  2007-05-01       Impact factor: 15.419

Review 3.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

4.  Induction of IL-33 expression and activity in central nervous system glia.

Authors:  Chad A Hudson; George P Christophi; Ross C Gruber; Joel R Wilmore; David A Lawrence; Paul T Massa
Journal:  J Leukoc Biol       Date:  2008-06-13       Impact factor: 4.962

Review 5.  Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.

Authors:  Khaled S Abdelkawy; Kelsey Lack; Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

6.  The importance of nitric oxide and arginase in the pathogenesis of acute neuroinflammation: are those contra players with the same direction?

Authors:  Srdjan Ljubisavljevic; Ivana Stojanovic; Radmila Pavlovic; Dusica Pavlovic
Journal:  Neurotox Res       Date:  2014-04-26       Impact factor: 3.911

7.  Arginase-2 mediates renal ischemia-reperfusion injury.

Authors:  Wesley M Raup-Konsavage; Ting Gao; Timothy K Cooper; Sidney M Morris; W Brian Reeves; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-17

8.  SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Authors:  George P Christophi; Chad A Hudson; Ross C Gruber; Christoforos P Christophi; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2008-01-21       Impact factor: 5.662

Review 9.  Arginase: an emerging key player in the mammalian immune system.

Authors:  Markus Munder
Journal:  Br J Pharmacol       Date:  2009-09-17       Impact factor: 8.739

10.  Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Rebecca L Christophi; Ross C Gruber; Akos T Mersich; Scott D Blystone; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2009-04-27       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.